Adagene Presents New Phase 1b/2 Data on ADG126 and KEYTRUDA Combination Therapy for Metastatic CRC at ESMO Congress
Adagene Presents New Phase 1b/2 Data on ADG126 and KEYTRUDA Combination Therapy for Metastatic CRC at ESMO Congress
Adagene Inc. ("Adagene") (NASDAQ:ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced new ADG126 clinical data presented at the ESMO Congress, taking place in Barcelona, Spain, September 13-17.
Adagene Inc.（"Adagene"）（納斯達克: ADAG）是一家致力於改變新型抗體療法的發現和開發的公司，今天宣佈在西班牙巴塞羅那於9月13日至17日舉辦的ESMO大會上發佈了新的ADG126臨床數據。
The poster, titled Increased Therapeutic Index of Muzastotug (ADG126), a Masked Anti-CTLA-4 Antibody, in Combination with Pembrolizumab (Pembro) Enables Significant Clinical Benefits and Supports Further Clinical Development in Patients with Metastatic MSS CRC, reports data from an ongoing phase 1b/2 trial of Adagene's masked anti-CTLA-4 SAFEbody in combination with Merck & Co., Inc., Rahway, NJ, USA's anti-PD-1 therapy KEYTRUDA (pembrolizumab) (ADG126-P001; NCT05405595).
這個標題爲《Muzastotug（ADG126）的治療指數增加，與Pembrolizumab（Pembro）聯合能夠在轉移性MSS CRC患者中實現顯著的臨床益處並支持進一步的臨床開發》的海報報告來自Adagene的蓋有Anti-CTLA-4遮蔽體的1b/2期持續進行的試驗數據。該試驗針對患有轉移性結腸癌(metastatic MSS CRC)的患者，使用默克（Merck）及其子公司默沙東公司（Merck & Co., Inc.）在美國, 紐約衆安合併，的抗PD-1療法KEYTRUDA（Pembrolizumab）（ADG126-P001；NCT05405595）。
譯文內容由第三人軟體翻譯。
